TOPIC
Drug Development
3 stories covering drug development — fund closes, LP allocations, regulatory filings, deal flow, and fundraising signals from PipelineRoad's editorial team.
Neurocrine Acquires Soleno for $2.9 Billion to Add PWS Drug
Neurocrine Biosciences expands its rare disease portfolio through a $2.9 billion acquisition of Soleno Therapeutics, gaining Vykat XR for Prader-Willi syndrome.
Neurocrine Acquires Soleno for $2.9 Billion to Gain Vykat XR
Neurocrine Biosciences expands its rare disease portfolio by acquiring Soleno Therapeutics for $2.9 billion, adding Vykat XR for Prader-Willi syndrome.
Red Light Holland Engages Kala Bio’s AI for PEX010 Psilocybin Development
Red Light Holland has engaged Kala Bio’s Researgency.ai platform to advance the clinical development of Filament’s PEX010 botanical psilocybin drug candidate, as per a March 18, 2026 announcement.
Daily capital raising signals
Get fund close, LP allocation, and deal flow news before it hits the mainstream.
